Abstract

Chondroitin sulphate captured an increasing amount of attention in the field of drug delivery systems. Nanoparticles and chondroitin sulphate were combined in different ways to form effective target nanocarriers. The study aimed to evaluate the biomedical application of chondroitin sulphate with nanoparticles in drug delivery systems. We searched PubMed, Google Scholar, and MEDLINE for studies that included data for the application of chondroitin sulphate and nanoparticles in targeting drug delivery published in English up to 25 February 2020. OHAT (Office of Health Assessment and Translation) Risk-of-Bias Tool was used to assessing the quality and risk of bias of each study. We performed a qualitative synthesis of findings from included studies. The toxicity of developed drugs has been evaluated using cell viability percentage and 50% inhibitory concentration of drugs. Twenty original articles reported the application of chondroitin sulphate on drug delivery systems were selected. Drug loading and encapsulation efficiency were from 2% to 16.1% and from 39.50% to 93.97%, respectively. The drug release was fast at start time and followed by a slow and sustain released stage. The risk of bias was rated as high in two out of twenty studies. Most of the studies presented baseline characteristics and outcomes appropriately.

摘要

硫酸软骨素在药物递送系统领域受到越来越多的关注。纳米颗粒和硫酸软骨素以不同的方式结合形成有效的目标纳米载体。该研究旨在评估硫酸软骨素与纳米颗粒在药物递送系统中的生物医学应用。我们在 PubMed、Google Scholar 和 MEDLINE 中搜索了研究，其中包括截至 2020 年 2 月 25 日以英文发布的硫酸软骨素和纳米颗粒在靶向给药中的应用数据。OHAT（健康评估和翻译办公室）风险偏差工具用于评估每项研究的质量和偏倚风险。我们对纳入研究的结果进行了定性综合。已开发药物的毒性已使用细胞活力百分比和药物的 50% 抑制浓度进行评估。选择了20篇报道硫酸软骨素在给药系统中的应用的原创文章。载药量和包封率分别为 2% 至 16.1% 和 39.50% 至 93.97%。药物释放在开始时很快，然后是缓慢的持续释放阶段。在 20 项研究中的 2 项中，偏倚风险被评为高。大多数研究都恰当地介绍了基线特征和结果。药物释放在开始时很快，然后是缓慢的持续释放阶段。在 20 项研究中的 2 项中，偏倚风险被评为高。大多数研究都恰当地介绍了基线特征和结果。药物释放在开始时很快，然后是缓慢的持续释放阶段。在 20 项研究中的 2 项中，偏倚风险被评为高。大多数研究都恰当地介绍了基线特征和结果。